Biotechnology

CStone announces first patient dosed in the global proof-of-concept study of CS1001 in combination with Bayer's regorafenib

SUZHOU, China, Jan. 24, 2020 /PRNewswire/ -- CStone Pharmaceuticals ("CStone" or the "Company", HKEX: 2616) recently announced that it has dosed the first patient inAustralia in a clinical trial of CS1001, an investigational PD-L1 inhibitor developed by CStone, in combination with regorafenib, an...

2020-01-24 14:26 569

CyberMDX Research Team Discovers Collection of GE Medical Device Vulnerabilities -- "MDhex"

CISA ICS has Issued an Advisory Containing 6 High-Severity CVEs for GE CARESCAPE, ApexPro, and Clinical Information Center (CIC) systems NEW YORK, Jan. 24, 2020 /PRNewswire/ -- A collection of six cybersecurity vulnerabilities has been discovered in a range of GE Healthcare devices popular ...

2020-01-24 02:48 468

Inovio Selected by CEPI to Develop Vaccine Against New Coronavirus

PLYMOUTH MEETING, Pa., Jan. 24, 2020 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced the Coalition for Epidemic Preparedness Innovations (CEPI) has awarded Inovio a grant of up to$9 million to develop a vaccine against the recently emerged strain of coronavirus (2019-nCo...

2020-01-24 00:26 948

Ascletis Received Approval of Clinical Trials in HBV Patients for ASC22, a Subcutaneously Administered PD-L1 Antibody

HANGZHOU and SHAOXING, China, Jan. 23, 2020 /PRNewswire/ -- Ascletis Pharma Inc. (Ascletis, 1672.HK) announces today the approval for ASC22 to conduct clinical trials in chronic hepatitis B patients inChina from China's National Medical Products Administration. ASC22 is a first-in-class, subcuta...

2020-01-23 09:52 601

Cognate BioServices closes Series B and completes acquisition of Cobra Biologics

MEMPHIS, Tennessee, Jan. 21, 2020 /PRNewswire/ -- Cognate BioServices, a leading contract development and manufacturing organization (CDMO) specialized in cell and cell-mediated gene therapy products today announced that it has completed the acquisition of Cobra Biologics, a leading CDMO speciali...

2020-01-22 08:04 419

China-Based Ivy Capital Invests in Betagenon's Clinical Stage AMPK Activator Program

STOCKHOLM, Jan. 20, 2020 /PRNewswire/ -- Balticgruppen Bio, the Umea based Biotech company focused on development of AMPK activator compounds, operating under the trademark Betagenon, has closed a funding round withChina based asset management firm Ivy Capital granting the company 3 MUSD of fundi...

2020-01-20 11:14 348

QBiotics receives first registration for tigilanol tiglate with European Medicines Agency approval of Stelfonta(R)

* STELFONTA® (tigilanol tiglate) approved by the European Medicines Agency (EMA), making it the first pharmaceutical treatment available for all grades of canine non-metastatic mast cell tumours (MCT)[1] * The approval marks the first registration of QBiotic's, lead compound tigilanol tiglate...

2020-01-20 07:00 612

Innovent Out-Licenses Commercial Rights for Avastin® Biosimilar to Coherus BioSciences in the United States and Canada

SUZHOU, China, Jan. 14, 2020 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent" or the "Company") (HKEX: 01801), a biopharmaceutical company that develops and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic and other major diseases, today announced tha...

2020-01-14 08:00 5728

Evolution 2.0 Prize: Unprecedented $10 Million Offered To Replicate Cellular Evolution

CHICAGO, Jan. 14, 2020 /PRNewswire/ --  An incentive prize ten times the size of the Nobel – believed to be the largest single award ever in basic science – is being offered to the person or team solving the largest mystery in history: how genetic code inside cells got there, and how cells intent...

2020-01-14 03:23 493

Exonate Announces Collaboration With Janssen to Develop a New Eye Drop for the Treatment of Retinal Vascular Diseases Including Wet Age-related Macular degeneration (AMD) and Diabetic Macular Oedema (DMO)

The program, facilitated by Johnson & Johnson Innovation, has the potential to improve the treatment of patients with retinal vascular diseases and transform the lives of those suffering from vision loss. CAMBRIDGE, England, Jan. 13, 2020 /PRNewswire/ -- Exonate, an early stage biotechnology com...

2020-01-13 16:00 412

Nanoform Appoints Head of US Sales

HELSINKI, Jan. 13, 2020 /PRNewswire/ -- Nanoform, an innovative nanoparticle medicine enabling company, has appointedSally Langa as Head of US Sales. The new role will enable Nanoform to continue its rapid growth with a strengthened presence in the US market. As Head of US Sales, Sally Langa wil...

2020-01-13 15:21 350

FHA-Food & Beverage spotlights tech innovation and industry transformation in new FoodTech Zone

SINGAPORE, Jan. 9, 2020 /PRNewswire/ -- From novel farming methods to connected kitchens, thetechnological and investment potential in the food tech space has grown dynamically in recent years. InSingapore...

2020-01-09 12:03 657

Publication of a Toxicological Study: A Milestone for Jennewein Biotechnologie for the GRAS Approval of the HMO-mix

RHEINBREITBACH, Germany, Jan. 9, 2020 /PRNewswire/ -- Jennewein Biotechnology announces another milestone in the worldwide approval of a new product generation, the "HMO-Mix." The data of the toxicological study, with the title "A Safety Evaluation of Mixed Human Milk Oligosaccharides in Rats," w...

2020-01-09 02:26 555

Waters Corporation Lauded by Frost & Sullivan for Developing the First Truly Smart Mass Spectrometer, the BioAccord LC-MS System

The system was designed to enhance productivity, positioning the user to acquire and process data with a purpose-built LC-MS platform SANTA CLARA, California, Jan. 8, 2020 /PRNewswire/ -- Based on its analysis of the global biopharmaceutical analytical instrumentation market, Frost & Sullivan ...

2020-01-08 21:30 5484

Hummingbird Bioscience Publishes Preclinical Data Demonstrating Efficacy of HMBD-001 in HER3 Driven Cancers

* HER3 activation is implicated in tumor progression and in acquired resistance to EGFR and HER2 therapies * Study, published in Molecular Cancer Therapeutics, found HMBD-001 to be able to uniquely block HER3 dimerization interface and potently inhibit tumor growth SINGAPORE, Jan. 8, 2020 /PR...

2020-01-08 10:40 362

Continued Success of Novoheart to Receive R&D Grants: Innovation Technology Fund for Developing Smart Cardiac Screening Technologies

* Grant will fund advanced R&D and incorporation of artificial intelligence (AI) technology to accelerate drug development using Novoheart's bio-engineered human heart chambers and tissues * Potential advancements expected to increase scale and capabilities of Novoheart's MyHeart™ Platform an...

2020-01-07 17:39 1135

Mundipharma Announces Exclusive Deal for Biosolution's CartiLife(R) in South Korea

SINGAPORE, Jan. 7, 2020 /PRNewswire/ -- Mundipharma has announced today that it has sealed an exclusive sales agreement with Biosolution Co., Ltd, a Korea-based leader in cell-based biotechnology, to market and distribute its fourth-generation autologous chondrocyte implantation product, CartiLif...

2020-01-07 11:37 398

genOway and Merck Strengthen CRISPR/Cas9 Strategic Alliance by Extending Their Partnership to All Animal Cell Models

genOway acquires additional rights to develop all animal cell models using the CRISPR/Cas9 system LYON, France, Jan. 7, 2020 /PRNewswire/ -- genOway, a public company and leader in developing genetically modified research models, today announced an important milestone in extending its strategic ...

2020-01-07 09:00 503

Japanese Clinical Study of DiscGenics' Cell Therapy for Disc Degeneration Passes Initial Safety Review

SALT LAKE CITY and TOKYO, Jan. 7, 2020 /PRNewswire/ -- DiscGenics, Inc., a clinical stage biopharmaceutical company focused on developing regenerative cell-based therapies that alleviate pain and restore function in patients with degenerative diseases of the spine, today announced that IDCT has p...

2020-01-07 08:00 439

BAVENCIO Significantly Improved Overall Survival in Patients With Locally Advanced or Metastatic Urothelial Carcinoma

Not intended for US-, Canada- and UK-based media  - At the planned interim analysis, Phase III JAVELIN Bladder 100 study met the primary endpoint of prolonging overall survival (OS) as a first-line maintenance treatment versus standard of care - BAVENCIO is the first immunotherapy to signifi...

2020-01-06 20:00 3906
12345 ... 56